Ridesharing giant Uber (UBER) made its debut this week, raising $8.1 billion dollars at a market cap of $82 billion, making it the largest US IPO since Alibaba went public in 2014. Uber priced its IPO at $45, 4% below the midpoint of the $44...read more
Cortexyme, which is developing a novel therapy for Alzheimer's disease using a microbe inhibitor, raised $75 million by offering 4.4 million shares at $17, the midpoint of the $16 to $18 range. Cortexyme plans to list on the Nasdaq under the symbol CRTX. BofA...read more
If 2019 is indeed the "year of Uber," then the week ahead can only be the "week of Uber." After years of IPO speculation, Uber (UBER) is expected to raise $8.5 billion at the $47 midpoint, with insiders selling $1.3 billion in the...read more
Cortexyme, which is developing a novel therapy for Alzheimer's disease, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. Insiders...read more
US IPO Weekly Recap: Uber falls 8% in a disappointing debut
Ridesharing giant Uber (UBER) made its debut this week, raising $8.1 billion dollars at a market cap of $82 billion, making it the largest US IPO since Alibaba went public in 2014. Uber priced its IPO at $45, 4% below the midpoint of the $44...read more
Alzheimer's disease biotech Cortexyme prices IPO at $17 midpoint
Cortexyme, which is developing a novel therapy for Alzheimer's disease using a microbe inhibitor, raised $75 million by offering 4.4 million shares at $17, the midpoint of the $16 to $18 range. Cortexyme plans to list on the Nasdaq under the symbol CRTX. BofA...read more
US IPO Week Ahead: It's Uber uber alles with biggest IPO in 5 years
If 2019 is indeed the "year of Uber," then the week ahead can only be the "week of Uber." After years of IPO speculation, Uber (UBER) is expected to raise $8.5 billion at the $47 midpoint, with insiders selling $1.3 billion in the...read more
Alzheimer's biotech Cortexyme sets terms for $75 million IPO
Cortexyme, which is developing a novel therapy for Alzheimer's disease, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. Insiders...read more